- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
- Written by Gregory Fowler
Tobira's cenicriviroc, a dual CCR5 and CCR2 receptor blocker with both antiviral and anti-inflammatory action, appears effective and better tolerated than some currently approved drugs, according to data presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
A growing body of evidence indicates that chronic inflammation plays a role in non-AIDS conditions that are gaining importance as people with HIV reach middle and older age.
Joseph Gathe from Therapeutic Concepts in Houston presented findings from a Phase 2b study of cenicriviroc vs efavirenz (Sustiva) at an oral abstract session on March 5 and provided a summary at an accompanying press conference.
[Joseph Gaithe speaks at CROI 2013 press conference, Atlanta, March 5, 2013]
J Gathe, J Cade, E DeJesus, et al. Week-24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with Emtricitabine/Tenofovir, in Treatment-naïve HIV-1+ Adults with CCR5-tropic Virus. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 106LB.